Drug Trial Radar · NCT03901118
Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Mar 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Jul 1, 2019
Primary completion
Dec 18, 2020
Study completion Dec 18, 2020
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial will evaluate the efficacy and safety of chiauranib added to chemotherapy in patients with relapsed or refractory ovarian cancer, in the meantime, explore the pharmacokinetics characteristic after the combined treatment.
Conditions
- Ovarian Cancer
Interventions
chiauranibDrug
in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily
etoposideDrug
50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most
paclitaxelDrug
60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression-free survival (PFS)Time frame: assessed up to 1 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.